Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

키워드

참고문헌 (63)

1. Mathers CD., "Projections of global mortality and burden of disease from 2002 to 2030", PLoS Med, 3, pp.e442~ (2006)
2. Murray CJ., "Disability-adjusted life years(DALYs)for 291 diseases and injuries in 21 regions, 1990-2010 : a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2197~2223 (2012)
3. Fournier JC., "Antidepressant drug effects and depression severity : a patient-level meta-analysis", JAMA, 303, pp.47~53 (2010)
4. Nierenberg AA., "Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression", J Clin Psychiatry, 62(Suppl 16), pp.5~9 (2001)
5. Moncrieff J., "Efficacy of antidepressants in adults", BMJ, 331, pp.155~157 (2005)
6. Trivedi MH., "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
7. Amsterdam JD., "Treatment algorithms in treatment-resistant depression", Psychiatr Clin North Am, 19, pp.371~386 (1996)
8. Greden JF., "The burden of disease for treatment-resistant depression", J Clin Psychiatry, 62(Suppl 16), pp.26~31 (2001)
9. hase ME., "Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors : a meta-analysis of original data from 7 randomized controlled trials", J Clin Psychiatry, 66, pp.974~981 (2005)
10. Rush AJ., "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
11. Nierenberg AA., "Evolution of remission as the new standard in the treatment of depression", J Clin Psychiatry, 60(Suppl 22), pp.7~11 (1999)
12. Frank E., "Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence", Arch Gen Psychiatry, 48, pp.851~855 (1991)
13. Thase ME., "Remission with mirtazapine and selective serotonin reuptake inhibitors : a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression", Int Clin Psychopharmacol, 25, pp.189~198 (2010)
14. Singh A., "Pharmacogenomics--the potential of genetically guided prescribing", Aust Fam Physician, 36, pp.820~824 (2007)
15. Singh A., "Genetically guided prescribing : Hope or hype?", Acta Neuropsychiatr, 20, pp.50~51 (2008)
16. Singh AB., "Antidepressant pharmacogenetics", Curr Opin Psychiatry, 27, pp.43~51 (2014)
17. Winner JG., "A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder", Discov Med, 16, pp.219~227 (2013)
18. Shelton RC., "Intracellular mechanisms of antidepressant drug action", Harv Rev Psychiatry, 8, pp.161~174 (2000)
19. Malberg JE., "Antidepressant action : to the nucleus and beyond", Trends Pharmacol Sci, 26, pp.631~638 (2005)
20. Belmaker RH., "Major depressive disorder", N Engl J Med, 358, pp.55~68 (2008)
21. Porcelli S., "Meta-analysis of serotonin transporter gene promoter polymorphism(5-HTTLPR)association with antidepressant efficacy", Eur Neuropsychopharmacol, 22, pp.239~258 (2012)
22. Keers R., "Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project", Pharmacogenomics J, 11, pp.138~145 (2011)
23. Domschke K., "Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response", Int J Neuropsychopharmacol, 17, pp.1167~1176 (2014)
24. Dutheil F., "ABC transporters and cytochromes P450 in the human central nervous system : influence on brain pharmacokinetics and contribution to neurodegenerative disorders", Expert Opin Drug Metab Toxicol, 6, pp.1161~1174 (2010)
25. Kirchheiner J., "Pharmacogenetics of antidepressants and antipsychotics : the contribution of allelic variations to the phenotype of drug response", Mol Psychiatry, 9, pp.442~473 (2004)
26. Singh AB., "ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression", Transl Psychiatry, 2, pp.e198~ (2012)
27. Hicks JK., "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants", Clin Pharmacol Ther, 93, pp.402~408 (2013)
28. Preskorn S., "Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers", J Clin Psychopharmacol, 29, pp.39~43 (2009)
29. Nichols AI., "The absolute bioavailability of desvenlafaxine in healthy subjects", J Bioequiv Availab, 4, pp.18~23 (2012)
30. Thase ME., "An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder", CNS Spectr, 14, pp.144~154 (2009)
31. Linnet K., "A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs", Eur Neuropsychopharmacol, 18, pp.157~169 (2008)
32. Hartz AM., "ABC transporters in the CNS-an inventory", Curr Pharm Biotechnol, 12, pp.656~673 (2011)
33. Juliano RL., "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants", Biochim Biophys Acta, 455, pp.152~162 (1976)
34. Chen CJ., "Internal duplication and homology with bacterial transport proteins in the mdr1(P-glycoprotein)gene from multidrug-resistant human cells", Cell, 47, pp.381~389 (1986)
35. Callen DF., "Localization of the human multiple drug resistance gene, MDR1, to 7q21. 1", Hum Genet, 77, pp.142~144 (1987)
36. Isenbarger TA., "The most conserved genome segments for life detection on Earth and other planets", Orig Life Evol Biosph, 38, pp.517~533 (2008)
37. Eyal S., "Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography", Clin Pharmacol Ther, 87, pp.579~585 (2010)
38. Hoffmeyer S., "Functional polymorphisms of the human multidrug-resistance gene : multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo", Proc Natl Acad Sci U S A, 97, pp.3473~3478 (2000)
39. Kimchi-Sarfaty C., "A"silent"polymorphism in the MDR1 gene changes substrate specificity", Science, 315, pp.525~528 (2007)
40. Weiss J., "Inhibition of P-glycoprotein by newer antidepressants", J Pharmacol Exp Ther, 305, pp.197~204 (2003)
41. Uhr M., "Polymorphisms in the drug transporter geneABCB1 predict antidepressant treatment response in depression", Neuron, 57, pp.203~209 (2008)
42. Uhr M., "Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption", Neuropsychopharmacology, 22, pp.380~387 (2000)
43. Wang JS., "Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein", Biol Pharm Bull, 31, pp.231~234 (2008)
44. Kato M., "ABCB1(MDR1)gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.398~404 (2008)
45. Lin KM., "ABCB1 gene polymorphisms are associated with theseverity of major depressive disorder and its response to escitalopram treatment", Pharmacogenet Genomics, 21, pp.163~170 (2011)
46. Lee SH., "MRP1 polymorphisms associated with citalopram response in patients with major depression", J Clin Psychopharmacol, 30, pp.116~125 (2010)
47. Jia J., "Regulation and dysregulation of 3'UTR-mediated translational control", Curr Opin Genet Dev, 23, pp.29~34 (2013)
48. Bushra R., "Food-drug interactions", Oman Med J, 26, pp.77~83 (2011)
49. Tsai HH., "Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements : a systematic literature review", Int J Clin Pract, 66, pp.1056~1078 (2012)
50. Akamine Y., "Psychotropic drug-drug interactions involving P-glycoprotein", CNS Drugs, 26, pp.959~973 (2012)
51. Tod M., "Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes : a general approach", AAPS J, 15, pp.1242~1252 (2013)
52. Crettol S., "Pharmacogenomics in psychiatry : from therapeutic drug monitoring to genomic medicine", Clin Pharmacol Ther, 95, pp.254~257 (2014)
53. Spudich A., "Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia", Nat Neurosci, 9, pp.487~488 (2006)
54. Hermann DM., "Implications of ATP-binding cassette transporters for brain pharmacotherapies", Trends Pharmacol Sci, 28, pp.128~134 (2007)
55. Kilic E., "ABCC1 : a gateway for pharmacological compounds to the ischaemic brain", Brain, 131, pp.2679~2689 (2008)
56. ElAli A., "Apolipoprotein E controls ATPbinding cassette transporters in the ischemic brain", Sci Signal, 3, pp.ra72~ (2010)
57. ElAli A., "Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication", Stroke, 43, pp.1647~1653 (2012)
58. ElAli A., "Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells", Brain Pathol, 22, pp.175~187 (2012)
59. Cartwright TA., "Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers", J Cereb Blood Flow Metab, 33, pp.381~388 (2013)
60. Tao LY., "Cediranib(recentin, AZD2171)reverses ABCB1-and ABCC1-mediated multidrug resistance by inhibition of their transport function", Cancer Chemother Pharmacol, 64, pp.961~969 (2009)
61. Crisafulli C., "Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder", Psychiatry Res, 209, pp.121~123 (2013)
62. Niitsu T., "Pharmacogenetics in major depression : a comprehensive meta-analysis", Prog Neuropsychopharmacol Biol Psychiatry, 45, pp.183~194 (2013)
63. Thompson C., "Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care", Psychiatry Res (2014)

관련 논문AI추천